Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thermo Electron Restructuring Will Spawn Medical Firm Worth $350 Mil.

This article was originally published in The Gray Sheet

Executive Summary

The medical products company conceived as a result of Thermo Electron's recently announced strategic restructuring plan will most likely be spun off in the first quarter of 2001 as a dividend to investors.

You may also be interested in...



Thoratec Finds HeartMate In Thermo Cardiosystems; Deal Valued At $570 Mil.

Acquisition of Thermo Cardiosystems by Thoratec Laboratories will broaden Thoratec's heart-assist device R&D pipeline to include an alternative-to-transplant indication, provide expanded selling opportunities at 80 U.S. heart failure treatment centers, and generate combined revenues of $130-140 mil. in fiscal 2001.

Thoratec Finds HeartMate In Thermo Cardiosystems; Deal Valued At $570 Mil.

Acquisition of Thermo Cardiosystems by Thoratec Laboratories will broaden Thoratec's heart-assist device R&D pipeline to include an alternative-to-transplant indication, provide expanded selling opportunities at 80 U.S. heart failure treatment centers, and generate combined revenues of $130-140 mil. in fiscal 2001.

Sulzer Looking To Double Medical Device Revenues Over Next Two Years

Sulzer says it plans to roughly double the size of its core cardiovascular/orthopedic device and materials technology businesses within two years to approximately $2 bil. and at the same time maintain a "significant focus" on biotechnology.

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel